Logo

Boehringer Ingelheim’s NexGard PLUS Receives the US FDA’s Approval to Protect Dogs from Internal and External Parasites

Share this
boehringer

Boehringer Ingelheim’s NexGard PLUS Receives the US FDA’s Approval to Protect Dogs from Internal and External Parasites

Shots:

  • The US FDA has approved afoxolaner, moxidectin & pyrantel chewable tablets (NexGard PLUS), a new one-and-done monthly combination product for canine protection from fleas, ticks, heartworm disease, roundworms & hookworms
  • Multiple clinical studies showed that NexGard PLUS was safe & effective, ≥99.8% effective 24hrs. in killing adult fleas fast after weekly infestations for a full month after treatment, 100% effective in preventing heartworm disease in dogs, safe for puppies as young as 8wks. & in P-gp-deficient (MDR1-mutant) avermectin-sensitive dogs
  • Boehringer Ingelheim’s beef-flavored afoxolaner, moxidectin & pyrantel chewable tablets are expected to be available for veterinary clinics on July 2023

Ref: PR Newswire | Image: Boehringer Ingelheim

Related News:- Boehringer Ingelheim Reports the Commercial Availability of Cyltezo, an Interchangeable Biosimilar to Humira

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions